Heart Failure Unit, Department of Cardiology, St Vincent's University Hospital, Dublin 4, Ireland.
Ir J Med Sci. 2011 Jun;180(2):369-74. doi: 10.1007/s11845-010-0659-z. Epub 2010 Dec 14.
ICD implantation for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction (ejection fraction ≤ 35%) has increased since the publication of the SCD-HEFT and MADIT-II data. The aim of this study is to examine the effectiveness and safety of prophylactic ICD use in a community heart failure population and to assess the impact on patient's quality of life.
Seventy-one ICDs were inserted between the years 2002 and 2006. The mean follow-up from time of insertion was 24 ± 11 months. Eighteen patients (25%) had potentially life-saving therapy. Seven (10%) patients received inappropriate shocks. Complications were encountered in five patients (7%).
In a community heart failure population, prophylactic ICD implantation is associated with a high incidence of life-saving therapy, a low complication rate and a high level of tolerability. These data indicate translation of clinical trial benefits to the general heart failure population.
自 SCD-HEFT 和 MADIT-II 数据公布以来,ICD 已用于有左心室收缩功能障碍(射血分数≤35%)的患者的一级预防,以预防心源性猝死。本研究旨在检测预防性 ICD 在社区心衰人群中的有效性和安全性,并评估其对患者生活质量的影响。
2002 年至 2006 年期间共植入 71 个 ICD。从植入时间开始的平均随访时间为 24±11 个月。18 名患者(25%)接受了可能挽救生命的治疗。7 名患者(10%)接受了不适当的电击。5 名患者(7%)出现并发症。
在社区心衰人群中,预防性 ICD 植入与较高的救生治疗发生率、较低的并发症发生率和较高的耐受性相关。这些数据表明,临床试验的获益已转化为一般心衰人群。